Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES101 in patients with advanced solid tumors
NCT04009460Phase 1Terminated
- Sponsor
- Elpiscience
- Start
- Jun 2019
- Primary completion
- Apr 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of inbrx-105 in solid tumor (advanced stage) (2 arms), sponsored by Elpiscience. Primary endpoints: Maximum Tolerated Dose and Frequency of adverse events. Started Jun 2019; status: terminated.
02
Drugs
inbrx-105
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04009460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04009460.